Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer

Inclusion Criteria: * 1\) age: 18-70 years old, female; 2\) patients with primary breast cancer, T2 or above, diagnosed by histopathology; 3\) HR was positive and HER-2 was negative by IHC; 4\) according to the RECIST 1.1 standard, there should be at least one measurable objective focus with tumor diameter \> 2cm; 5\) ECoG physical fitness score 0-1; 6\) LVEF≥55%； 7\) bone marrow function: neutrophil ≥ 1.5 × 109 / L, platelet ≥ 100 × 109 / L, hemoglobin ≥ 90g / L; 8\) liver and kidney function: serum creatinine ≤ 1.5 times the upper limit of normal value; AST and alt ≤ 2.5 times the upper limit of normal value; total bilirubin ≤ 1.5 times the upper limit of normal value, or patients with Gilbert's syndrome ≤ 2.5 times the upper limit of normal value; 9\) patients have good compliance with the planned treatment, can understand the research process of this study and sign the written informed consent Exclusion Criteria: * 1\) previously received cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason; 2\) patients with stage IV metastasis at the initial diagnosis; 2\) New York Heart Association (NYHA) rating of patients with heart disease above grade II (including grade II); 3\) patients with serious systemic infection or other serious diseases; 4\) patients who are known to be allergic or intolerant to chemotherapy drugs or their adjuvants; 5\) in the past 5 years, there have been other malignant tumors, except the cured carcinoma in situ of cervix and skin cancer without melanoma; 6\) pregnancy or lactation, as well as childbearing age patients who refuse to take appropriate contraceptive measures during the trial; 7\) participated in other experimental studies within 30 days before the administration of the first study drug; 8\) patients not suitable for the study were judged by the researchers.